PE20090900A1 - Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene - Google Patents
Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contieneInfo
- Publication number
- PE20090900A1 PE20090900A1 PE2008001322A PE2008001322A PE20090900A1 PE 20090900 A1 PE20090900 A1 PE 20090900A1 PE 2008001322 A PE2008001322 A PE 2008001322A PE 2008001322 A PE2008001322 A PE 2008001322A PE 20090900 A1 PE20090900 A1 PE 20090900A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfanil
- triazolopyridacine
- met
- growth factor
- benzotiazole
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 title 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 4-FLUOROPHENYL Chemical class 0.000 abstract 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 abstract 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
REFERIDO A UN COMPUESTO DERIVADO DE 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL Y BENCIMIDAZOL DE FORMULA (I): DONDE --- ES UN ENLACE SIMPLE O DOBLE; Ra ES H, HALOGENO, ALCOXI, ENTRE OTROS; X ES S, SO o SO2; A ES NH O S; W ES H, ALQUILO SUSTITUIDO CON ALCOXI, HETEROCICLOALQUILO, NR3R4 O COR; R ES CICLOALQUILO O ALQUILO SUSTITUIDO OPCIONALMENTE CON NR3R4, ALCOXI, HIDROXI ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1,3-BENZOTIAZOL-2-IL)CARBAMATO DE METILO, 6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1,3-BENZOTIAZOL-2-AMINA, 1-(6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1H-BENCIMIDAZOL-2-IL)-3-(2-MORFOLIN-4-ILETIL)UREA. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE MET (RECEPTOR DEL FACTOR DE CRECIEMIENTO DE HEPATOCITOS) SIENDO UTIL EN EL TRATAMIENTO ANTIPROLIFERATIVO Y ANTIMETASTASICO, PRINCIPALMENTE EN ONCOLOGIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705789A FR2919870B1 (fr) | 2007-08-09 | 2007-08-09 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet |
| FR0801819A FR2929613B1 (fr) | 2008-04-02 | 2008-04-02 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090900A1 true PE20090900A1 (es) | 2009-08-06 |
Family
ID=40524792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001322A PE20090900A1 (es) | 2007-08-09 | 2008-08-07 | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene |
Country Status (41)
| Country | Link |
|---|---|
| US (3) | US8546393B2 (es) |
| EP (1) | EP2178881B1 (es) |
| JP (1) | JP5694767B2 (es) |
| KR (1) | KR101654376B1 (es) |
| CN (1) | CN101801973B (es) |
| AR (1) | AR068055A1 (es) |
| AU (1) | AU2008320791B2 (es) |
| BR (1) | BRPI0815606A2 (es) |
| CA (2) | CA2884102A1 (es) |
| CL (1) | CL2008002351A1 (es) |
| CO (1) | CO6251270A2 (es) |
| CR (1) | CR11252A (es) |
| CY (1) | CY1114906T1 (es) |
| DK (1) | DK2178881T3 (es) |
| DO (1) | DOP2010000040A (es) |
| EA (1) | EA023465B1 (es) |
| EC (1) | ECSP109944A (es) |
| ES (1) | ES2436657T3 (es) |
| GT (1) | GT201000023A (es) |
| HR (1) | HRP20131182T1 (es) |
| IL (1) | IL203734A (es) |
| JO (1) | JO2935B1 (es) |
| MA (1) | MA31685B1 (es) |
| ME (1) | ME00972B (es) |
| MX (2) | MX2010001593A (es) |
| MY (1) | MY152535A (es) |
| NI (1) | NI201000022A (es) |
| NZ (1) | NZ583177A (es) |
| PA (1) | PA8792501A1 (es) |
| PE (1) | PE20090900A1 (es) |
| PL (1) | PL2178881T3 (es) |
| PT (1) | PT2178881E (es) |
| RS (1) | RS53078B (es) |
| SG (1) | SG183077A1 (es) |
| SI (1) | SI2178881T1 (es) |
| TN (1) | TN2010000026A1 (es) |
| TW (1) | TWI429649B (es) |
| UA (1) | UA101328C2 (es) |
| UY (1) | UY31277A1 (es) |
| WO (1) | WO2009056692A2 (es) |
| ZA (1) | ZA201000912B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| EA201170222A1 (ru) * | 2008-07-18 | 2011-08-30 | Санофи-Авентис | НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ |
| FR2941229B1 (fr) * | 2009-01-21 | 2012-11-30 | Sanofi Aventis | Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| CA2730749A1 (fr) * | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Nouveaux derives imidazo[1,2-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment commeinhibiteurs de met |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941952B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| EP2396333B1 (en) * | 2009-02-10 | 2013-07-03 | AstraZeneca AB | Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer |
| UY32623A (es) * | 2009-05-11 | 2010-12-31 | Astrazeneca Ab | Derivados bicíclicos para afecciones asociadas al receptor de andrógenos |
| WO2011079804A1 (en) | 2009-12-31 | 2011-07-07 | Hutchison Medipharma Limited | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| TW201202242A (en) | 2010-03-30 | 2012-01-16 | Sanofi Aventis | 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors |
| FR2958292A1 (fr) * | 2010-03-30 | 2011-10-07 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| FR2966151B1 (fr) * | 2010-10-14 | 2012-11-09 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AR085183A1 (es) * | 2010-07-30 | 2013-09-18 | Lilly Co Eli | Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| TW201402121A (zh) * | 2012-07-12 | 2014-01-16 | Sanofi Sa | 包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 |
| ES2646916T3 (es) | 2012-11-19 | 2017-12-18 | Bayer Pharma Aktiengesellschaft | Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US10047071B1 (en) | 2018-01-15 | 2018-08-14 | King Saud University | Dihydropyrimidinone derivatives |
| CN110317216A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑并哒嗪类衍生物在医药领域的应用 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CN110041311B (zh) * | 2019-05-20 | 2021-03-19 | 东南大学 | 一种荧光探针分子ml-fp及其制备方法和应用 |
| KR20220020890A (ko) * | 2019-06-12 | 2022-02-21 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 염 형태 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499995A1 (fr) | 1981-02-13 | 1982-08-20 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus. |
| NZ510013A (en) * | 1998-09-11 | 2003-11-28 | Warner Lambert Co | Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors |
| EP1298125A1 (en) | 2001-09-26 | 2003-04-02 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
| US7728017B2 (en) * | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| PT1966214T (pt) * | 2005-12-21 | 2017-02-03 | Janssen Pharmaceutica Nv | Triazolpiridazinas como moduladores de tirosina quinase |
| EP2032578A2 (en) * | 2006-05-30 | 2009-03-11 | Pfizer Products Incorporated | Triazolopyridazine derivatives |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| WO2008051808A2 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
-
2008
- 2008-08-05 PA PA8792501A patent/PA8792501A1/es unknown
- 2008-08-06 EA EA201070235A patent/EA023465B1/ru not_active IP Right Cessation
- 2008-08-06 NZ NZ583177A patent/NZ583177A/en not_active IP Right Cessation
- 2008-08-06 UA UAA201002523A patent/UA101328C2/uk unknown
- 2008-08-06 KR KR1020107005087A patent/KR101654376B1/ko not_active Expired - Fee Related
- 2008-08-06 MY MYPI2010000582A patent/MY152535A/en unknown
- 2008-08-06 MX MX2010001593A patent/MX2010001593A/es active IP Right Grant
- 2008-08-06 PT PT08845285T patent/PT2178881E/pt unknown
- 2008-08-06 HR HRP20131182AT patent/HRP20131182T1/hr unknown
- 2008-08-06 SG SG2012055091A patent/SG183077A1/en unknown
- 2008-08-06 SI SI200831106T patent/SI2178881T1/sl unknown
- 2008-08-06 DK DK08845285T patent/DK2178881T3/da active
- 2008-08-06 CA CA2884102A patent/CA2884102A1/fr not_active Abandoned
- 2008-08-06 MX MX2014000226A patent/MX340060B/es unknown
- 2008-08-06 BR BRPI0815606 patent/BRPI0815606A2/pt active Search and Examination
- 2008-08-06 EP EP08845285.9A patent/EP2178881B1/fr active Active
- 2008-08-06 RS RSP20130542 patent/RS53078B/sr unknown
- 2008-08-06 ES ES08845285T patent/ES2436657T3/es active Active
- 2008-08-06 AU AU2008320791A patent/AU2008320791B2/en not_active Ceased
- 2008-08-06 CA CA2695628A patent/CA2695628C/fr not_active Expired - Fee Related
- 2008-08-06 ME MEP-2010-7A patent/ME00972B/me unknown
- 2008-08-06 CN CN200880106250.6A patent/CN101801973B/zh not_active Expired - Fee Related
- 2008-08-06 JP JP2010519489A patent/JP5694767B2/ja not_active Expired - Fee Related
- 2008-08-06 PL PL08845285T patent/PL2178881T3/pl unknown
- 2008-08-06 WO PCT/FR2008/001172 patent/WO2009056692A2/fr not_active Ceased
- 2008-08-07 AR ARP080103452 patent/AR068055A1/es unknown
- 2008-08-07 JO JO2008361A patent/JO2935B1/en active
- 2008-08-07 TW TW97130120A patent/TWI429649B/zh not_active IP Right Cessation
- 2008-08-07 PE PE2008001322A patent/PE20090900A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002351A patent/CL2008002351A1/es unknown
- 2008-08-08 UY UY31277A patent/UY31277A1/es not_active Application Discontinuation
-
2010
- 2010-01-13 TN TNP2010000026A patent/TN2010000026A1/fr unknown
- 2010-01-26 US US12/693,736 patent/US8546393B2/en not_active Expired - Fee Related
- 2010-01-28 DO DO2010000040A patent/DOP2010000040A/es unknown
- 2010-01-28 GT GT201000023A patent/GT201000023A/es unknown
- 2010-01-29 CO CO10009506A patent/CO6251270A2/es active IP Right Grant
- 2010-02-03 CR CR11252A patent/CR11252A/es unknown
- 2010-02-03 NI NI201000022A patent/NI201000022A/es unknown
- 2010-02-04 IL IL20373410A patent/IL203734A/en not_active IP Right Cessation
- 2010-02-08 EC ECSP109944 patent/ECSP109944A/es unknown
- 2010-02-08 ZA ZA2010/00912A patent/ZA201000912B/en unknown
- 2010-03-01 MA MA32659A patent/MA31685B1/fr unknown
-
2013
- 2013-08-27 US US14/011,110 patent/US9115134B2/en not_active Expired - Fee Related
- 2013-12-13 CY CY20131101130T patent/CY1114906T1/el unknown
-
2015
- 2015-06-04 US US14/731,246 patent/US9321777B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090900A1 (es) | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20090876A1 (es) | Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
| PE20061073A1 (es) | Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| BRPI1015568B8 (pt) | derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| PE20060573A1 (es) | Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas | |
| PE20130191A1 (es) | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida | |
| PE20080211A1 (es) | Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih | |
| PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
| PE20081383A1 (es) | Inhibidores benzoimidazolicos de trpv1 | |
| UY31865A (es) | Derivados de urea heterocíclicos y métodos para la utilización de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |